enow.com Web Search

  1. Ads

    related to: apixaban vs aspirin atrial fibrillation

Search results

  1. Results from the WOW.Com Content Network
  2. Direct factor Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

    [4] [5] [6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non-valvular atrial fibrillation (AF) who have other risk factors, and prevent blood clots after routine knee and hip replacement surgery. [2] [3] [7]

  3. Apixaban - Wikipedia

    en.wikipedia.org/wiki/Apixaban

    Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.

  4. Discovery and development of direct Xa inhibitors - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting due to atherosclerosis. Rivaroxaban was the first FXa inhibitor on the market and then followed by apixaban, edoxaban and betrixaban.

  5. ELIQUIS® (apixaban) Approved In Japan For The ... - AOL

    www.aol.com/news/2012-12-26-eliquis-apixaban...

    ELIQUIS ® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol ...

  6. This Analyst Says Artivion's Sell Off Seems Overdone After ...

    www.aol.com/news/analyst-says-artivions-sell-off...

    On Friday, Artivion Inc (NYSE: AORT) stopped the PROACT Xa clinical trial after the Data Safety Monitoring Board (DSMB) indicated that there was a lack of evidence supporting the non-inferiority ...

  7. Talk:Apixaban - Wikipedia

    en.wikipedia.org/wiki/Talk:Apixaban

    A 2011 trial, AVERROES, showed that, in patients with atrial fibrillation who have failed or are not candidates for vitamin K antagonist therapy, apixaban (5 mg twice daily), as compared with aspirin, reduced the risk of stroke or systemic embolism by 55%. Major bleeding events were similar for both groups.

  1. Ads

    related to: apixaban vs aspirin atrial fibrillation